Community Bank & Trust Waco Texas Sells 2,404 Shares of Pfizer Inc. (NYSE:PFE)

Community Bank & Trust Waco Texas cut its holdings in Pfizer Inc. (NYSE:PFE) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,405 shares of the biopharmaceutical company’s stock after selling 2,404 shares during the quarter. Community Bank & Trust Waco Texas’ holdings in Pfizer were worth $1,894,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Wells Trecaso Financial Group LLC grew its position in Pfizer by 2.5% in the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock valued at $416,000 after acquiring an additional 350 shares in the last quarter. Washington Trust Advisors Inc. grew its position in Pfizer by 0.7% in the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock valued at $1,424,000 after acquiring an additional 360 shares in the last quarter. PSI Advisors LLC boosted its stake in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 385 shares during the period. Western Pacific Wealth Management LP boosted its stake in shares of Pfizer by 10.5% in the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 386 shares during the period. Finally, Waddell & Associates LLC boosted its stake in shares of Pfizer by 1.6% in the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after buying an additional 388 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.5 %

NYSE:PFE opened at $25.87 on Tuesday. The firm has a market cap of $146.58 billion, a P/E ratio of 18.34, a PEG ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock’s 50 day simple moving average is $26.28 and its 200-day simple moving average is $27.72. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.65%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 121.99%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PFE. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Guggenheim reiterated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.